BACK TO CONTENTS   |    PDF   |   


Structure-based analysis of curcumin and conventional drugs targeting tumor-inducing protein PHF20



Vibha Agrawal, Aradhya Mishra, Shivani Tiwari, Akhileshwar Kumar Srivastava*



Department of Biotechnology, Sri Agrasen Kanya P.G. College, Bulanala, Varanasi - 221003, India;


Akhileshwar Kumar Srivastava - Email:; Phone: +91-8604664864; *Corresponding author


Article Type




Received October 20, 2018; Revised October 30, 2018, Accepted October 31, 2018; Published November 03, 2018



Recently, the PHF20 has been reported as tumor inducer protein by suppressing the activity of tumor suppressor protein p53. Conventional drugs (albendazole, doxazosin, and propranolol) are used for treatment of cancer causing side effect. The secondary metabolite curcumin is employed in various diseases treatment including cancer. The present study is to explore curcumin in comparison to selected conventional drugs by using molecular docking. The online database “Molinspiration online server” detected the physicochemical pharmacokinetics and drug likeness score of curcumin and conventional drugs. Results from Molinspiration online server showed that curcumin did not violate the “Lipinski five rule” for drug. The lead compound for molecular docking exhibited the potential interaction to the active site of PHF20. The resulted binding energy of albendazole and doxazosin were -21.97 and -26.64 respectively. The binding energy (-18.12 kcal/mol) of curcumin was higher than propranolol (17.62 kcal/mol). Thus, curumin has greater potential to interact for further consideration as an anti-cancerous regimen.



Curcumin, conventional drugs, PHF20, molecular docking



Agarwal et al. Bioinformation 14(9): 477-481 (2018)


Edited by

P Kangueane






Biomedical Informatics



This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.